Compare Quest Diagnostics Inc (DGX) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs LYFT Inc — how do they compare? Quest Diagnostics Inc trades at $237.43 (market cap $26.21B), while LYFT Inc trades at $16.46 (market cap $6.64B). The key difference: Quest Diagnostics Inc is far larger — about 3.9× LYFT Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while LYFT Inc pays none. Which is the better fit depends on your goals.
| DGX | LYFT | |
|---|---|---|
Market Cap | $26.21B | $6.64B |
Sector | Health | Industrials |
52-Week High | $238.50 | $24.57 |
52-Week Low | $173.49 | $12.65 |
Enterprise Value | $31.97B | $6.11B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Lyft (LYFT) trades at $16.48, down 4.52% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong revenue growth to $6.32 billion in 2025 and a net income of $2.84 billion, with a positive cash flow trend. Recent Q2 2026 earnings missed EPS estimates but beat on revenue, with record active riders exceeding 30 million.
Lyft's outlook is supported by expanding robotaxi partnerships and international growth, but faces risks from rising costs and competition. Analyst consensus is a 'Hold' with a $19.17 price target, indicating modest upside potential from current levels amid mixed sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
